A Columbia clinical trial led by Hua-Jay Cherng, MD, will partner with Foresight Diagnostics to evaluate more personalized cancer treatments for patients with diffuse large B-cell lymphoma (DLBCL)..
Columbia physician-scientist Ryan Moy, MD, PhD, is pioneering research in gastric cancer, including a promising new clinical trial using pill-based therapies to treat diffuse gastric cancer.
Study led by Melissa Beauchemin, PhD, highlights that inadequate translation and interpretation services in the U.S. contributes to lack of representation in cancer clinical trials.
Experts reviewed withdrawals across fast-track drug approval programs, finding that overall, these programs contribute positively to drug development with little safety concerns.
A team of Columbia physician-scientists have opened a trial of a noninvasive, focused ultrasound approach to open the blood-brain barrier to better treat pediatric brain tumors.
Tannishtha Reya, PhD, is establishing the new Irving Cancer Drug Discovery Program, devoted to helping faculty accelerate research discoveries in their labs to the clinic.
Dr. Jeffrey Bruce: "This new approach has the potential to transform treatment for patients with brain cancer, where the outlook for survival remains very poor."
Melissa Accordino, MD, tackles solutions to long-term side effects, like peripheral neuropathy, that some breast cancer survivors experience after overcoming the disease.
During First Lady Jill Biden's Columbia Sept. 21 visit, she singles out patient, Mario Sambula and his special connection with clinical trials nurse navigator, Brianne Bodin.
As part of the Biden Administration's Cancer Moonshot initiative, First Lady Jill Biden and Queen Letizia of Spain visited Columbia University's cancer center on Sept. 21.
First Lady Jill Biden and Queen Letizia of Spain underscore Columbia Cancer's work in addressing health inequities, improving diversity in clinical trials and advancing critical cancer research.